Asari Radix et Rhizoma consumption lacks relevance for hepatocellular carcinoma in patients: A retrospective cohort study
- Author:
Zhi-e FANG
1
;
Yuming GUO
1
;
Zhilei WANG
1
;
Tingting HE
1
;
Jiabo WANG
1
;
Zhaofang BAI
1
;
Xiaohe XIAO
1
;
Zhi-e FANG
2
;
Yuming GUO
2
;
Zhilei WANG
2
;
Tingting HE
2
;
Jiabo WANG
2
;
Zhaofang BAI
2
;
Xiaohe XIAO
2
Author Information
- Publication Type:Journal Article
- Keywords: aristolochic acid; Asari Radix et Rhizoma; hepatitis B virus (HBV); hepatocellular carcinoma; safety awareness
- From: Chinese Herbal Medicines 2022;14(3):470-475
- CountryChina
- Language:Chinese
- Abstract: Objective: Although some studies have linked Asari Radix et Rhizoma (Asari Radix) administration to hepatocellular carcinoma (HCC), few studies have examined the association between the development of HCC and use of Asari Radix among patients in mainland China. This study aimed to evaluate the real-world association between Asari Radix and HCC in patients to strengthen the understanding of Asari Radix safety. Methods: A retrospective cohort study among hepatitis B virus (HBV)-monoinfected patients and non-HBV-monoinfected patients were performed. Patients over 18 years of age were eligible for inclusion. Prescription records of inpatients and outpatients were inquired to distinguish Asari Radix users and nonusers. The risk of developing HCC among Asari Radix users and nonusers in the HBV cohort and the non-HBV cohort was analyzed. Results: There were 49 500 HBV and 133 148 non-HBV patients involved in the two cohorts. Among HBV patients (2 901 users; 46 599 nonusers), the prevalence of HCC in Asari Radix users was lower than that in nonusers (145.70 vs. 265.43 per 10
